The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are frequently activated in leukemia and other hematopoietic disorders by upstream mutations in cytokine receptors, aberrant chromosomal translocations as well as other genetic mechanisms. The Jak2 kinase is frequently mutated in many myeloproliferative disorders. Effective targeting of these pathways may result in suppression of cell growth and death of leukemic cells. Furthermore it may be possible to combine various chemotherapeutic and antibody-based therapies with low molecular weight, cell membrane-permeable inhibitors which target the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/ STAT pathways to ultimately suppress the survival pathways, induce apoptosis and inhibit leukemic growth. In this review, we summarize how suppression of these pathways may inhibit key survival networks important in leukemogenesis and leukemia therapy as well as the treatment of other hematopoietic disorders. Targeting of these and additional cascades may also improve the therapy of chronic myelogenous leukemia, which are resistant to BCR-ABL inhibitors. Furthermore, we discuss how targeting of the leukemia microenvironment and the leukemia stem cell are emerging fields and challenges in targeted therapies. Leukemia (2008) 22, 708–722; doi:10.1038/leu.2008.27; published online 13 March 2008 Keywords: MEK; PI3K; Akt; signal transduction; inhibitors; chemotherapeutic drugs

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy / Mccubrey, Ja; Steelman, Ls; Abrams, Sl; Bertrand, Fe; Ludwig, De; Bäsecke, J; Libra, M; Stivala, F; Milella, M; Tafuri, A; Lunghi, P; Bonati, Antonio; Martelli, Am. - In: LEUKEMIA. - ISSN 0887-6924. - 22:(2008), pp. 708-722. [10.1038/leu.2008.27]

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

LUNGHI P;BONATI, Antonio;
2008-01-01

Abstract

The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are frequently activated in leukemia and other hematopoietic disorders by upstream mutations in cytokine receptors, aberrant chromosomal translocations as well as other genetic mechanisms. The Jak2 kinase is frequently mutated in many myeloproliferative disorders. Effective targeting of these pathways may result in suppression of cell growth and death of leukemic cells. Furthermore it may be possible to combine various chemotherapeutic and antibody-based therapies with low molecular weight, cell membrane-permeable inhibitors which target the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/ STAT pathways to ultimately suppress the survival pathways, induce apoptosis and inhibit leukemic growth. In this review, we summarize how suppression of these pathways may inhibit key survival networks important in leukemogenesis and leukemia therapy as well as the treatment of other hematopoietic disorders. Targeting of these and additional cascades may also improve the therapy of chronic myelogenous leukemia, which are resistant to BCR-ABL inhibitors. Furthermore, we discuss how targeting of the leukemia microenvironment and the leukemia stem cell are emerging fields and challenges in targeted therapies. Leukemia (2008) 22, 708–722; doi:10.1038/leu.2008.27; published online 13 March 2008 Keywords: MEK; PI3K; Akt; signal transduction; inhibitors; chemotherapeutic drugs
2008
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy / Mccubrey, Ja; Steelman, Ls; Abrams, Sl; Bertrand, Fe; Ludwig, De; Bäsecke, J; Libra, M; Stivala, F; Milella, M; Tafuri, A; Lunghi, P; Bonati, Antonio; Martelli, Am. - In: LEUKEMIA. - ISSN 0887-6924. - 22:(2008), pp. 708-722. [10.1038/leu.2008.27]
File in questo prodotto:
File Dimensione Formato  
leukemia rev 1.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 313.25 kB
Formato Adobe PDF
313.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/1895286
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 214
  • ???jsp.display-item.citation.isi??? 209
social impact